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Abstract 
 
Objectives 
 
Automated blood pressure devices are frequently introduced in maternity care without prior 
validation for their accuracy in pregnancy. Our objectives were to, firstly, establish the accuracy 
in pregnancy of a locally used device (Welch Allyn 300) and, secondly, to audit its impact on the 
diagnosis and treatment of hypertension. 
 
Study design  
 
Validation study  
The device was evaluated using the grading criteria of the European Society of Hypertension 
International Protocol (ESH-IP) (2010). Two observers took nine same-arm measurements 
alternating between the Welch Allyn and the mercury sphygmomanometer. Thirty-three women 
of any gestation were included.   
 
Clinical audit 
One observer took three same-arm measurements alternating between the Welch Allyn and the 
mercury sphygmomanometer. One hundred women of any gestation referred with suspected 
hypertension were included. The main outcome measures were the proportion diagnosed with 
hypertension or commenced on anti-hypertensive treatment on the presenting visit when using 
either the manual or the automated device.  
 
Main Outcome Measures 
 
Grading criteria of the ESH-IP (2010) and proportion of women diagnosed with hypertension or 
commenced on antihypertensive therapy at the presenting visit when using either manual 
sphygmomanometry or the Welch Allyn device. 
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Results 
 
The Welch Allyn 300 series failed to meet the criteria of the ESH-IP (2010) for pregnancy. 
Compared to the mercury device, it under diagnosed hypertension by 48% and need for 
treatment by 80%.  
 
Conclusions 
 
The Welch Allyn 300 cannot be recommended for the measurement of blood pressure in 
pregnancy. Its use leads to the under-diagnosis and under-treatment of gestational hypertension. 
 
Keywords:  Blood pressure; hypertension; oscillometric; preeclampsia; pregnancy; validation; 
Welch-Allyn Vital Signs
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Introduction  
 
Hypertensive disorders affect approximately 10 percent of women during pregnancy and are the 
second direct cause of maternal death worldwide [1]. The accurate measurement of blood 
pressure is integral to the diagnosis and management of hypertension in pregnancy.   
 
The mercury sphygmomanometer, the gold standard for the measurement of blood pressure, is 
becoming obsolete due to concerns regarding mercury toxicity [2, 3]. Automated devices are 
increasingly replacing mercury but their accuracy is disputed due to the empirical non-
standardised algorithms used [4]. In attempt to address these concerns, validation protocols have 
been introduced and refined since the early 1990s [5-8]. The more recent version of the 
European Society of Hypertension International Protocol (ESH-IP) tightened the requirements 
for validation as a reflection of improvements in technology [7].  
 
National guidelines do not state which method of blood pressure measurement should be used in 
pregnancy but only that it should be accurate and, if not mercury sphygmomanometry, validated 
[9]. To date, only 15 automated devices are validated for pregnancy of which five are accurate in 
preeclampsia [10-12]. Unfortunately, many hospitals use a centralised procurement system for 
blood pressure monitors and little attention is paid to their accuracy in different populations.  At 
King’s College Hospital, the Welch-Allyn Vital Signs 300 series has been centrally obtained and 
distributed to all maternity areas.  
 
The two fundamental aspects of antenatal management of hypertension in pregnancy are, firstly, 
to be able to identify when a pregnant women becomes hypertensive and, secondly, to identify 
whether the blood pressure is above a pre-determined threshold at which treatment is required.  
The impact of using an automated device that is inaccurate for use in pregnancy or preeclampsia 
has not been previously reported.   
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In this study, we used the ESH-IP 2010 to evaluate the accuracy of the Welch-Allyn Vital Signs 
300 series in pregnancy and preeclampsia. In addition, as this device was already in clinical use 
in our unit, we sought to determine its impact on the diagnosis and decision for treatment of 
hypertension amongst women referred with suspected hypertension to our Maternal Assessment 
Unit (MAU). Finally, we evaluated the association between maternal characteristics and device 
agreement, in an attempt to define future strategies to improve the device performance.  
 
Methods 
 
Validation study 
 
Procedure  
 
Women of any gestation with an arm circumference of 25.3 to 34.4cm were recruited from the 
maternity areas at Kings College Hospital (London, UK). Participants provided written consent 
at the time of recruitment. Women with unclear Korotkoff sounds (N=5), arrhythmia (N=1), or if 
unable to provide informed consent (N=1), were excluded from the study. Thirty-eight 
participants were excluded due to blood pressure range completion (N=28) or range adjustment 
(N=10).   
 
The validation procedure recommended by the ESH-IP (2010) was followed [6].  Two observers 
were trained in blood pressure measurements using a CD-ROM programme produced by the 
British Hypertension Society. An independent supervisor assessed both observers individually 
prior to commencing the study to ensure correct blood pressure measurement technique.  
 
The two observers took nine sequential same-arm measurements from each participant, 
alternating between the mercury sphygmomanometer and the Welch-Allyn Vital Signs 300 series 
device, using a double-headed stethoscope (Littman Class II Stethoscope). The participant was 
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seated, legs uncrossed and arm supported at heart level. An independent supervisor would 
request the mercury measurement to be repeated if the inter-observer discrepancy exceeded 
4mmHg.  A period of 30 seconds to 1 minute was allowed between readings to avoid venous 
congestion.   
 
The first measurement by the two observers using the mercury sphygmomanometer was the 
entry blood pressure and was used to categorise the participant into a blood pressure range as 
specified by the ESH-IP.  The second measurement using the automated device was used to 
orientate the device to the participant.  The subsequent seven measurements were used in the 
final analysis.  
 
Analysis  
 
The mean differences between the device and the observer measurements were calculated to 
determine the accuracy and a visual representation of this was provided in the form of Bland – 
Altman plots.  Based on these results, the device will ‘pass’ only if it satisfies the validation 
requirements.  
 
Audit on the diagnosis and treatment of hypertension 
 
Procedure 
 
This was a prospective observational audit, which was carried out in parallel with the validation.  
We measured blood pressure sequentially using the Welch-Allyn Vital Signs 300 series device, 
which was routinely used in the MAU, and a mercury sphygmomanometer. We aimed to assess 
the differences in the blood pressure readings between the two devices and the impact that this 
would have on the diagnosis of hypertension in pregnancy within the index visit. In addition, we 
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aimed at assessing if maternal somatometric and demographic variables could explain potential 
differences between the two devices.  
 
One hundred and fifteen women of any gestation who were referred with suspected hypertension 
were recruited from the MAU at Kings College Hospital. Verbal consent was obtained from each 
participant. Fifteen women were excluded due to unclear Korotkoff sounds (N=5), arrhythmias 
(N=2), incomplete outcome data (N=4), or due to being unable to provide informed consent 
(N=4).    
 
The entry blood pressure was the blood pressure reading that prompted the referral.  Each 
participant then had three sequential same-arm blood pressure readings with an interval of 30 
seconds to one minute. A trained observer alternated between the mercury sphygmomanometer 
(first and third reading) and the Welch-Allyn Vital Signs 300 series test device (second reading). 
Three readings were taken to allow for two comparisons between the device and the manual 
sphygmomanometer and, thus, help limit bias.  
 
Analysis  
 
The outcome of each pregnancy was followed using our Maternity Database. Hypertension in 
pregnancy as defined by the American College of Obstetricians and Gynaecologists is blood 
pressure equal or greater than 140/90mmHg on two occasions, four hours apart. Patients were 
classed as having chronic hypertension if this predated pregnancy or was prior to 20 weeks 
gestation.  Hypertension occurring beyond 20 weeks gestation was defined as pregnancy-induced 
hypertension (PIH) or preeclampsia if in the presence of significant proteinuria (i.e. ≥ 0.3g of 
protein in a 24-hour urine collection) [13]. 
 
Based on the definitions stated, we determined the number of patients who would have been 
diagnosed with new-onset hypertension had the Welch-Allyn Vital Signs 300 series or the 
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manual readings been used.  To address the second issue of when to initiate anti-hypertensive 
treatment, again we looked at the number of patients who would have commenced medication 
based on either the Welch-Allyn Vital Signs 300 series or the mercury sphygmomanometer 
blood pressure readings.  We used two thresholds for commencing treatment: 150/100mmHg, as 
recommended by the National Institute of Health and Clinical Excellence (NICE) [13], and 
140/90mmHg, if tighter blood pressure control was to be achieved [9].  
 
Statistics 
 
As with the validation study, mean differences between the observer and the device were 
calculated and plotted on a Bland – Altman plot.   
 
The normality of the distribution of the data was assessed by the Kolmogoroff-Smirnoff test. 
Univariate and multivariate linear and logistic regression were used to estimate and compare the 
magnitude of the effects of age, ethnicity, body mass index (BMI), gestational age, and systolic 
or diastolic blood pressure level (as measured by the mercury) on the differences between the 
two devices.  
 
Results 
 
Validation Study  
 
Study participants  
 
Seventy-eight women were recruited in order to complete the blood pressure categories as 
specified in the ESH-IP (2010). Thirty-three women were included in the final analysis. The 
characteristics of the study participants along with the number of observer measurements within 
each blood pressure category are presented in Table 1.  
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Amongst our cohort, 24 percent (N=8) had normal pregnancy outcomes, 48 percent (N=16) had 
preeclampsia, 18 percent (N=6) had PIH and 9 percent (N=3) were known to have chronic 
hypertension and had not developed preeclampsia during their pregnancy.   
 
Validation criteria 
 
The validation criteria of Phase 1 of the ESH-IP (2010) and the results of the validation analysis 
are presented in Table 2. The Welch-Allyn Vital Signs 300 series did not fulfil the protocol 
requirements and so has failed Phase 1 and 2 of the ESH-IP (2010) both for systolic and diastolic 
blood pressure.  Bland-Altman plots of the data are given for systolic and diastolic blood 
pressure (Figure 1). These plots illustrate the relationship between the Welch-Allyn Vital Signs 
300 series device and the mercury sphygmomanometer readings for the better observer.  
 
Audit on the diagnosis and treatment of hypertension 
 
Study participants 
 
One hundred participants with new onset hypertension referred to the MAU were included in this 
audit.  Group characteristics are outlined in Table 3.  Their pregnancies were followed up 
prospectively until delivery. Fourteen percent (N=14) of the participants had chronic 
hypertension and 86 percent (N=86) had developed new-onset hypertension beyond 20 weeks 
gestation. Of the women with chronic hypertension, one developed preeclampsia, while from the 
new onset hypertension group, 48 women developed PIH and 38 women preeclampsia.     
 
Clinical impact results 
  
Four of the 14 women with chronic hypertension and 17 of the 86 women with new-onset 
hypertension were found to be normotensive on the day of referral by both the Welch-Allyn 
Vital Signs 300 series and the mercury sphygmomanometer. Of the new-onset group they all 
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subsequently developed preeclampsia (N=8) or PIH (N=9).  
 
The mercury sphygmomanometer, using either the first or the second reading, classified 80 
percent of new-onset patients (N= 69) on the day of referral as hypertensives (chi-square 37.8, 
p<0.0001). If only the first manual reading is used, then 77 percent (N= 66) of patients would 
have been classed as having new-onset hypertension (chi-square 32.1, p<0.0001) versus 72 
percent (N= 62) if only the second manual blood pressure reading was used (chi-square 25.4, 
p<0.0001). On the contrary, the Welch-Allyn Vital Signs 300 series device classified as new-
onset hypertensives only 32.6 percent (N=28) of referred patients (Figure 2). 
 
Similar discrepancies between the performances of the two devices were seen regarding the need 
for antihypertensive treatment. If treatment was to be initiated above a threshold of greater than 
or equal to 150/100mmHg, 44 (N= 44) and 9 (N= 9) percent of all patients (chronic and new 
onset) were identified as requiring anti-hypertensives by the mercury or the Welch-Allyn Vital 
Signs 300 series device, respectively (chi-square 29.6, p<0.0001). If treatment was to be initiated 
above a threshold of greater than or equal to 140/90mmHg, then 78 (N= 78) and 34 (N=34) 
percent of patients (chronic and new onset) were identified as requiring anti-hypertensives by the 
mercury or the Welch-Allyn Vital Signs 300 series device, respectively (chi-square 37.5, 
p<0.0001) (Figure 2).  
 
Amongst the hypertensive women (N=79), 13 (16.5%), 11 (14%) and 11 (14%) of them 
developed severe hypertension, thrombocytopenia and liver dysfunction, respectively.   
 
Regression analysis  
 
Device disagreement both in systolic and diastolic blood pressure was greater with increasing 
mercury blood pressure readings. This relationship was present when either the first or second 
manual readings were used. The device difference for the first manual systolic blood pressure 
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(Device Difference = 44.1-0.4*SBP1, p<0.0001, R2=0.32, Supplement Figure 1) and second 
manual systolic blood pressure (Device Difference = 35.4-0.3*SBP2, p<0001, R2=0.27, Figure 
3) were higher with increasing blood pressure values.  Device disagreement in diastolic blood 
pressure was higher with increasing levels of blood pressure and maternal age both for the first 
(Device Difference = 19.1-0.3*DBP1+0.2*age, p<0.0001, R2=0.31, Supplement Figure 1) and 
second manual reading (Device Difference = 22.0-0.4*DBP2, p<0001, R2=0.3, Figure 3). All 
other associations with BMI, ethnicity, heart rate and gestational age were not significant 
predictors of the device disagreement.   
 
Discussion 
 
Main Findings 
 
This study has demonstrated that the Welch-Allyn Vital Signs 300 series failed to reach the 
required standards of the ESH-IP (2010) for the measurement of blood pressure during 
pregnancy and preeclampsia. The underestimation of the device became even more pronounced 
with increasing levels of blood pressure and maternal age. This discrepancy reached as high as 
28 and 44mmHg, for systolic and diastolic blood pressure, respectively. Furthermore, the clinical 
significance of using an automated device underperforming in pregnancy was demonstrated by a 
prospective observational audit.  In our population, when assessed by the mercury 
sphygmomanometer, 80 percent of women, who were eventually diagnosed with pregnancy-
related hypertension, were found to be hypertensive. In contrast, only 32 percent of these women 
were identified when using the Welch-Allyn device, an underestimation of 48 percent.  
 
NICE Guidelines recommends treatment when blood pressure is 150/100mmHg or above [9] in 
order to avoid placental hypoperfusion resulting in fetal growth restriction. However, a recent 
randomised controlled trial (RCT) demonstrated no significant difference in perinatal outcomes 
between those who obtained tight (i.e. target diastolic blood pressure of 85mmHg) versus less-
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tight blood pressure control. In contrast, women with less-tight blood pressure control were 
almost twice as likely to develop severe hypertension [14]. As the appropriate cut-off for 
initiating antihypertensive treatment is not yet established, we assessed the impact of using 
mercury or an automated device for either of those thresholds.  
 
About 80 and 56 percent fewer women would have been commenced on antihypertensive 
medication if their management had been based on the readings from the automated device for a 
threshold for treatment of 150/100 or 140/90mmHg, respectively. Based on our findings, it is 
possible that using an automated device that has not been validated for use in pregnancy may 
contribute to, first, failure to recognise women at risk of preeclampsia and, second, failure to 
then control their blood pressure.  
 
In our study, realising how much the Welch-Allyn underestimated, we felt it was unethical but to 
base the management of the referred pregnancies on the readings of the mercury device. 
Therefore, we cannot present differences in pregnancy outcomes between the two devices. 
However, a Cochrane meta-analysis [15] and a recent RCT [14] have demonstrated a doubling in 
the risk of maternal severe hypertension, a risk factor for intracranial haemorrhage,[16] when 
mild hypertension is not treated to levels below 140/90. Furthermore, the same RCT has shown a 
more than doubling risk of thrombocytopenia and impaired liver function with less tight BP 
control.[14] In our data, assuming the total cohort had it’s management based on the Welch-
Allyn, it could have translated to a more than doubling in the rates of severe pre-eclampsia, 
thrombocytopenia and impaired liver function from the ones observed.   
 
Strengths and Limitations 
 
Simultaneous same-arm readings are the ideal for comparing two methods of measuring blood 
pressure. As this is not achievable when comparing mercury to automated devices, two 
alternatives exist; simultaneous opposite-arm and sequential same-arm measurements.  In the 
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first, the inter-arm difference will vary from one measurement to the next. In the latter, three 
measurements are taken alternating between the mercury and the automated device. By 
calculating the difference between the second automated reading and the first and third manual 
readings and using the most favourable difference in the final analysis, parity with the 
simultaneous same-arm measurements is restored [17]. This explains the rationale behind the 
ESH-IP (2010) and emphasises the strength in our audit methodology 
 
Furthermore, we assessed the association of maternal demographic variables and device 
discrepancy for both first and second mercury readings. This provided additional reassurance 
that the relationship demonstrated between the inaccuracy of the device, degree of hypertension 
and maternal demographics was consistent.  
 
Interpretation  
 
Our results agree with previous studies, which validated predecessors of this model and 
recommended caution with its use in hypertensive patients, whether they were pregnant [18] or 
not [19]. However, using the ESH-IP (2010), our results do not support the use of this model 
neither in normotensive nor in hypertensive pregnancies. This could be a reflection of the more 
stringent validation criteria of the ESH-IP (2010) applied in our study or a change in the device 
functional algorithms with more recent models [20].  
 
The under-diagnosis of hypertension as a result of under-reading by an automated device is in 
agreement with data from non-pregnant populations.  Turner et al showed that the diagnosis of 
hypertension is extremely sensitive to systematic errors in the measurement of blood pressure. 
They demonstrated that approximately 50 and 30 percent of patients with diastolic hypertension 
would be missed if diastolic blood pressure was underestimated by only 5 or 3 mmHg, 
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respectively. Underestimation of systolic blood pressure by 3 or 5 mmHg, would lead to the 
under-diagnosis of 15 and 25 percent of patients with systolic hypertension, respectively [20]. 
 
In our study, the underestimation in measuring both systolic and diastolic blood pressure was 
most discernible at higher readings. Similarly, Braam et al demonstrated that the accuracy of 
most currently available automated devices decreased at increasing blood pressure levels. This 
was attributed to a combination of the increasing variability seen in hypertensive patients and the 
fluctuation during sequential measurements [21].  One can argue that at very high readings the 
diagnosis of hypertension will not be affected. It is at mild levels of hypertension that there will 
be a more pronounced clinical impact from the lack of agreement and, as a result, a delay in 
instigating any treatment. Lim et al, compared the impact of using a validated automated device 
on the diagnosis of hypertension.  In their study, 60 and 40 percent of misclassification between 
the two devices was for the diagnosis of pre-hypertension and Stage-1 hypertension, 
respectively, while there was agreement in the classification of Stage-2 hypertension [22].  
 
The impact of the use of automated devices on the diagnosis of hypertension and disease 
outcome is well established in non-pregnant populations.  However, the studies evaluating its 
impact in pregnant populations are sparse and all involved devices that were not validated for use 
in pregnancy or preeclampsia. The discrepancy between automated monitors and mercury 
sphygmomanometers is not similar across all devices, as each company employs different 
algorithms for the signal acquisition and analysis [4, 23].  It is, therefore, important that each 
device is specifically validated across all patient groups and the clinical impact of its use is 
shown in prospective studies. This is the reason why in our study, not only did we validate the 
Welch-Allyn device but we also showed the impact that its use had for the classification of 
hypertension.  
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The impact of demographic variables on the disagreement between mercury and automated 
devices has been previously demonstrated in non-pregnant populations [22, 24]. Larger studies 
are needed to assess whether adding these in the device algorithms would improve the 
performance of automated monitors. 
 
Conclusion  
 
The Welch-Allyn Vital Signs 300 underestimates systolic and diastolic blood pressure and, 
consequently, the diagnosis of hypertension and need for treatment at the presenting visit. 
Further studies are needed on the impact of the above on pregnancy outcome. 
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Table 1: Validation study (ESH-IP 2010) - Subject details.  
Subject details (N=33) 
Age (years) 
Range (Low:High) 22:41 
Mean (SD) 31.4 (5.1) 
Arm circumference (cm) 
Range (Low:High) 24:32.5 
Mean (SD) 28.9 (2.6) 
Recruitment Systolic BP (mmHg) 
Range (Low:High) 85:177 
Mean (SD) 136.9 (24.9) 
Recruitment Diastolic BP (mmHg)  
Range (Low:High) 45:110 
Mean (SD) 85.8 (18.1) 
Observer measurements in each recruitment range 
Systolic BP Diastolic BP 
Overall range (low:high) 82:171 Overall range (low:high) 48:121 
Low (<130) 55 Low (<130) 27 
Medium (130-160) 38 Medium (130-160) 48 
High (>160) 6 High (>160) 24 
Maximum difference 49 Maximum difference 24 
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Table 2: Validation study – Grading criteria and results for the ESH-IP (2010) 
 
Part 1 
Pass requirements 
 
<5mmHg 
 
<10mmHg <15mmHg Grade 1 
Two of 73 87 96  
All of 65 81 93  
Achieved     
SBP 41 66 84 Fail 
DBP 18 59 81 Fail 
Part 2 
Pass requirements 
2/3 ≤ 5mmHg 
 
0/3 ≤ 5mmHg 
 
 Grade 2 
All of >24 <3   
Achieved    
SBP 13 14  Fail 
DBP 4 22  Fail 
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Table 3:  Clinical impact audit – Subject details  
 
Subject details (N=100) 
Blood pressure status 
- Chronic hypertension, n 14 
- Pre-eclampsia, n 38 
- Pregnancy-induced hypertension, n 48 
Age (years) 
Low:High 18:57 
Mean (SD) 32.95(±6.4) 
BMI (kg/m2) 
Low:High 19:52 
Mean (SD) 27.95 (±6.3) 
Ethnicity 
Black/African, n 34 
Black/Carribbean, n 17 
White/Caucasian, n 45 
South East Asian, n 4 
Gestational age (weeks) 
Low:High 11:41.4 
Mean (SD) 35.4 (±8.23) 
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Figure Legends 
 
• Figure 1A: 
o Title: Difference of systolic blood pressure - observer 
o Description: Bland Altman plot showing the difference in systolic blood pressure 
between the Welch Allyn Vital Signs 300 device readings and the mean of two 
observer readings in all 33 participants. 
• Figure 1B: 
o Title: Difference of diastolic blood pressure – observer 
o Description: Bland Altman plot showing the difference in diastolic blood pressure 
between the Welch Allyn Vital Signs 300 device readings and the mean of two 
observer readings in all 33 participants. 
• Figure 2A:  
o Title: Diagnosis of hypertension.  
o Description: Proportion of patients classified as hypertensive on the index visit by 
the first, second or highest of the two mercury measurements (grey boxes) and by the 
Welch-Allyn Vital Signs 300 (black box).  
o Abbreviations: BP – blood pressure 
• Figure 2B: 
o Title: Treatment of hypertension. 
o Description: Proportion of patients identified as needing treatment on the index visit 
by the first, second or highest of the two mercury sphygmomanometer measurements 
(grey boxes) and by the Welch-Allyn Vital Signs 300 (black box). On the left, if a cut 
off of 150/100 mmHg and on the right if a cut off of 140/90 mmHg was used to 
determine the need for treatment.  
o Abbreviations: BP – blood pressure 
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• Figure 3A 
o Title: Systolic blood pressure 
o Description: Scatter plot describing the relationship between the difference of the 
device and the second mercury reading (Y-axis) and the second mercury reading (x-
axis). The regression line (95% CI) illustrating the above relationship is also shown. 
o Abbreviations: CI – confidence interval 
• Figure 3B:  
o Title: Diastolic blood pressure  
o Description: (Left) Scatter plot describing the relationship between the difference of 
the device and the second mercury measurement (Y-axis) and the mercury second 
measurement (x-axis). The regression line (95% CI) illustrating the above 
relationship is also shown. (Right) Scatter plot describing the relationship between the 
difference of the device and the second mercury measurement (Y-axis) and the 
maternal age (x-axis). The regression line (95% CI) illustrating the above relationship 
is also shown. 
o Abbreviations: CI – confidence interval 
• Supplementary Figure 1A 
o Title: Systolic blood pressure 
o Description: Scatter plot describing the relationship between the difference of the 
device and the first mercury reading (Y-axis) and the first mercury reading (x-axis). 
The regression line (95% CI) illustrating the above relationship is also shown. 
o Abbreviations: CI – confidence interval 
• Supplementary Figure 1B  
o Title: Diastolic blood pressure  
o Description: (Left) Scatter plot describing the relationship between the difference of 
the device and the first mercury measurement (Y-axis) and the first second 
measurement (x-axis). The regression line (95% CI) illustrating the above 
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relationship is also shown. (Right) Scatter plot describing the relationship between the 
difference of the device and the first mercury measurement (Y-axis) and the maternal 
age (x-axis). The regression line (95% CI) illustrating the above relationship is also 
shown. 
o Abbreviations: CI – confidence interval 
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Highlights 
 
An inaccurate automated device negatively impacts the diagnosis and treatment of 
gestational hypertension. 
 
 
• Welch-Allyn Vital Signs 300 series underestimates blood pressure in pregnancy.  
• The underestimation is more pronounced at higher blood pressures and maternal age.  
• The Welch-Allyn device leads to a 48% under-diagnosis of gestational hypertension. 
• Its underestimation results in under-treatment of gestational hypertension by 80%. 
 
 
 
 
